Back to Search
Start Over
Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients.
- Source :
-
Future cardiology [Future Cardiol] 2024 Jul 04, pp. 1-13. Date of Electronic Publication: 2024 Jul 04. - Publication Year :
- 2024
- Publisher :
- Ahead of Print
-
Abstract
- Aim: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower anthracycline-induced cardiotoxicity. Methods: PubMed and Google Scholar were searched until September 2023 for studies regarding SGLT2i for treating anthracycline-induced cardiotoxicity. Overall mortality and cardiovascular events were considered. Using a random-effects model, data pooled RR and HR at a 95% confidence interval (CI). Results: 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33-0.82); p  = 0.005; I <superscript>2</superscript> = 32%], HF hospitalization [RR = 0.20 (0.04-1.02); p  = 0.05; I <superscript>2</superscript> = 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20-1.16); p  = 0.11, I <superscript>2</superscript> = 0%]. Conclusion: SGLT2i mitigates mortality and hospitalization due to heart failure, improving cancer patient's chances of survival by undergoing anthracycline treatment.
Details
- Language :
- English
- ISSN :
- 1744-8298
- Database :
- MEDLINE
- Journal :
- Future cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 38962942
- Full Text :
- https://doi.org/10.1080/14796678.2024.2363673